Log in

HemaCare Stock Price, News & Analysis (OTCMKTS:HEMA)

+0.10 (+0.56 %)
(As of 10/20/2019 07:26 AM ET)
Today's Range
Now: $18.10
50-Day Range
MA: $17.48
52-Week Range
Now: $18.10
Volume17,042 shs
Average Volume9,619 shs
Market Capitalization$247.79 million
P/E RatioN/A
Dividend YieldN/A
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolOTCMKTS:HEMA



Sales & Book Value

Annual SalesN/A



Market Cap$247.79 million
Next Earnings DateN/A
OptionableNot Optionable

Receive HEMA News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMA and its competitors with MarketBeat's FREE daily newsletter.

HemaCare (OTCMKTS:HEMA) Frequently Asked Questions

What is HemaCare's stock symbol?

HemaCare trades on the OTCMKTS under the ticker symbol "HEMA."

What is the consensus analysts' recommendation for HemaCare?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HemaCare in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HemaCare.

Has HemaCare been receiving favorable news coverage?

News articles about HEMA stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. HemaCare earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for HemaCare.

Who are some of HemaCare's key competitors?

What other stocks do shareholders of HemaCare own?

Who are HemaCare's key executives?

HemaCare's management team includes the folowing people:
  • Mr. Peter C. van der Wal, Pres, CEO & Director (Age 62)
  • Ms. Rochelle J. Martel M.B.A., CPA, Chief Financial Officer
  • Ms. Maria Pia Muniz, Sr. VP of Operations
  • Mr. Lou Juliano, Sr. VP of Global Sales & Bus. Devel.
  • Dr. Dominic Clarke, Global Head of Cell Therapy

How do I buy shares of HemaCare?

Shares of HEMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is HemaCare's stock price today?

One share of HEMA stock can currently be purchased for approximately $18.10.

How big of a company is HemaCare?

HemaCare has a market capitalization of $247.79 million. View Additional Information About HemaCare.

What is HemaCare's official website?

The official website for HemaCare is http://www.hemagen.com/.

How can I contact HemaCare?

HemaCare's mailing address is 15350 SHERMAN WAY SUITE 350, VAN NUYS CA, 91406. The company can be reached via phone at 818-226-1968 or via email at [email protected]

MarketBeat Community Rating for HemaCare (OTCMKTS HEMA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about HemaCare and other stocks. Vote "Outperform" if you believe HEMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel